<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17954" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Atomoxetine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fedder</surname>
            <given-names>Douglas</given-names>
          </name>
          <aff>American University of Antigua</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Himanshu</given-names>
          </name>
          <aff>The University of Arizona</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Douglas Fedder declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Himanshu Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17954.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Atomoxetine is indicated for treating attention deficit hyperactivity disorder (ADHD) in adults and children over six years. Although atomoxetine is only FDA-approved for treating ADHD, it is sometimes used off-label to treat adult patients with treatment-resistant depression. This activity outlines the indications, mechanism of action, administration, adverse effects, contraindications, and monitoring of atomoxetine.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of atomoxetine.</p></list-item><list-item><p>Outline the contraindications of atomoxetine.</p></list-item><list-item><p>Review the appropriate follow-up monitoring for atomoxetine therapy.</p></list-item><list-item><p>Summarize some interprofessional team strategies for improving care coordination and communication to enhance patient outcomes and minimize adverse events with atomoxetine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17954&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17954">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17954.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-approved Indication</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Attention deficit hyperactivity disorder (ADHD) in adults and children over the age of 6<xref ref-type="bibr" rid="article-17954.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Neurogenic orthostatic hypotension<xref ref-type="bibr" rid="article-17954.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>ADHD in adults with the comorbid partially responsive major depressive disorder<xref ref-type="bibr" rid="article-17954.r3">[3]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17954.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Atomoxetine is a selective, presynaptic, norepinephrine reuptake inhibitor known as a NET inhibitor. Atomoxetine is the R(-) isomer. The R(-) isomer is an approximately nine times more potent norepinephrine reuptake inhibitor than the S(+) isomer.<xref ref-type="bibr" rid="article-17954.r4">[4]</xref>&#x000a0;Atomoxetine inhibits the presynaptic norepinephrine transporter (NET), preventing the reuptake of NE throughout the brain and inhibiting dopamine reuptake in specific brain regions such as the prefrontal cortex (PFC). The novel mechanism of atomoxetine also includes several new brain imaging studies and animal model studies.<xref ref-type="bibr" rid="article-17954.r5">[5]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption</bold>: Atomoxetine is well-absorbed after oral administration and is minimally affected by food. Administration of atomoxetine capsules with a standard high-fat meal in adults did not affect the extent of oral absorption of atomoxetine (AUC) but reduced absorption rate, resulting in a 37% lower Cmax, and delayed Tmax by 3 hours. Specific studies regarding the intestinal permeability of atomoxetine are not available; however, two studies on the bioavailability of atomoxetine determined that in extensive metabolizers, the bioavailability of atomoxetine was 63%, and in poor metabolizers, the bioavailability was 94%. The differences in bioavailability were attributed to differences in first-pass metabolism in the liver rather than differences in intestinal absorption. Another study comparing the bioavailability of atomoxetine capsules versus solution found no differences in bioavailability between the two. Another study looking at the absorption of atomoxetine found no differences across a range of gastrointestinal pH levels, implying that concurrent use of antacids and proton pump inhibitors should not be cause for concern when administering atomoxetine.<xref ref-type="bibr" rid="article-17954.r4">[4]</xref></p>
        <p><bold>Distribution</bold>: At therapeutic concentrations, 98% of atomoxetine in plasma is bound to protein, primarily albumin. The volume of distribution(Vd) is 0.85 L/kg implying that atomoxetine distributes primarily into total body water. The volume of distribution is similar across the patient weight range after normalizing for body weight. Researchers studied the CNS pharmacokinetics of atomoxetine in rats. The penetration of the blood-brain barrier (BBB) is crucial in the pharmacokinetics of atomoxetine, as the CNS is the site of action for atomoxetine. The brain extracellular fluid (ECF) ratio to atomoxetine plasma concentrations suggests that movement across the BBB is primarily via diffusion rather than an active transport mechanism.<xref ref-type="bibr" rid="article-17954.r6">[6]</xref>&#x000a0;In vitro studies have shown that atomoxetine is approximately 98.7% protein-bound, with albumin making up 97.5% of this binding. The high protein binding of atomoxetine raises concerns about possible drug-to-drug interactions due to displacement from plasma proteins. However, in vitro studies have demonstrated that human plasma protein binding was only reduced by toxic concentrations of acetylsalicylic acid (aspirin), indicating minimal clinical risk for drug-to-drug interactions.<xref ref-type="bibr" rid="article-17954.r4">[4]</xref></p>
        <p><bold>Metabolism</bold>: Atomoxetine is metabolized predominantly through the CYP2D6 enzymatic pathway. Coadministration of atomoxetine capsules with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a marked increase in atomoxetine plasma exposure, and dosing adjustment may be necessary. The main oxidative metabolite is 4-hydroxyatomoxetine. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but has lower plasma concentrations. Approximately 7% of Caucasians and less than 1% of Asians are poor metabolizers of CYP2D6 and this polymorphism results in altered atomoxetine pharmacokinetics. Oral bioavailability can alter, e.g., 63% in extensive metabolizers of CYP2D6 and 94% in poor metabolizers. The estimated half-life can alter, e.g., 5.2 hours in extensive metabolizers and 21.6 hours in poor metabolizers.<xref ref-type="bibr" rid="article-17954.r4">[4]</xref></p>
        <p><bold>Excretion:&#x000a0;</bold>The primary metabolite of atomoxetine, 4-hydroxy atomoxetine, is biologically equipotent to atomoxetine. The half-life of atomoxetine is approximately 5 hours and may reach up to 24 hours in poor metabolizers. The active metabolite of atomoxetine has a half-life of 6 to 8 hours and may reach up to 40 hours in poor metabolizers. Atomoxetine is excreted primarily through the urine (83%) and feces (17%).<xref ref-type="bibr" rid="article-17954.r7">[7]</xref></p>
      </sec>
      <sec id="article-17954.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Atomoxetine is available in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg capsules as a hydrochloride salt. Patients can take atomoxetine with or without food as a once-daily dose in the morning or two evenly divided doses in the morning and afternoon. Capsules should not be opened and should be taken whole.</p>
        <list list-type="bullet">
          <list-item>
            <p>Initial dosing for adults is 40 mg per&#x000a0;day and can be increased after a minimum of 3 days to achieve therapeutic effects. A maximum daily dose is 100 mg per&#x000a0;day.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Initial dosing for children older than six years and less than 70 kg is 0.5 mg/kg per day. The maximum daily dose of 1.4 mg/kg per day or 100 mg, whichever is less.</p>
          </list-item>
        </list>
        <p>Atomoxetine is the first non-stimulant medication to receive FDA approval for the treatment of ADHD. Previous medicines approved to treat ADHD, such as methylphenidate and other amphetamines, are CNS stimulants. Therefore, they may carry a higher risk of abuse and addiction than atomoxetine. Clinical studies of atomoxetine have shown a lack of abuse potential, consistent with preclinical predictions. While atomoxetine has been demonstrated to be effective in treating ADHD, many studies have shown stimulant medications have greater efficacy.&#x000a0;Also, stimulant medications typically have an almost immediate clinical effect, whereas atomoxetine may take several weeks for full noticeable therapeutic action.&#x000a0;Patients may stop taking atomoxetine without tapering.<xref ref-type="bibr" rid="article-17954.r8">[8]</xref><xref ref-type="bibr" rid="article-17954.r9">[9]</xref></p>
        <p>
<bold>Special Population</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold><bold>Dosage adjustment based on Pharmacogenetics:</bold>&#x000a0;</bold>Patients who are CYP2D6 poor metabolizers should<italic toggle="yes">&#x000a0;</italic>be prescribed 40 mg per day. The dose may be increased to 80 mg per day after four weeks if there is an inadequate response.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hepatic Impairment</bold>: Atomoxetine exposure (AUC) is increased, compared with normal subjects, in subjects with moderate (Child-Pugh Class B) (2-fold increase) and severe (Child-Pugh Class C) (4-fold increase) hepatic insufficiency. Dosage adjustment is recommended for patients with moderate or severe hepatic insufficiency. Hence for moderate hepatic impairment(Child-Pugh class B), 50% dose reduction is recommended. For severe hepatic impairment (Child-Pugh class C), a 75% dose reduction is recommended.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Renal Impairment</bold>: Patients with renal impairment usually do not need dose adjustment per the manufacturer's product labeling.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pregnancy Considerations</bold>: Atomoxetine is pregnancy category C medicine.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Breastfeeding considerations</bold>: No serious adverse events were reported in the breastfed infants, but alternate drugs for the treatment of ADHD&#x000a0;are&#x000a0;preferred.<xref ref-type="bibr" rid="article-17954.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17954.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Atomoxetine has a United States (US) boxed warning for suicidal ideation in children and adolescents. An analysis of multiple short-term trials revealed increased suicidal ideation in children and adolescents treated with atomoxetine (0.4%) compared to those treated with a placebo (0%). Children and adolescents who start on atomoxetine require close monitoring for suicidal ideation and unusual changes in behavior. Clinicians should always perform a risk-benefit analysis before starting anyone on atomoxetine.<xref ref-type="bibr" rid="article-17954.r11">[11]</xref></p>
        <p>
<bold>Common Adverse Drug Reactions (</bold>
<bold>Greater than 10%)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache (19%)<xref ref-type="bibr" rid="article-17954.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Insomnia (1% to 19%)</p>
          </list-item>
          <list-item>
            <p>Hyperhidrosis (4% to 15%)</p>
          </list-item>
          <list-item>
            <p>Xerostomia (17% to 35%)</p>
          </list-item>
          <list-item>
            <p>Delayed ejaculation and priapism(8% to 21%)<xref ref-type="bibr" rid="article-17954.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Nausea (7% to 26%)</p>
          </list-item>
          <list-item>
            <p>Decreased appetite (15% to 23%)</p>
          </list-item>
          <list-item>
            <p>Abdominal pain (7% to 18%)</p>
          </list-item>
          <list-item>
            <p>Vomiting (4% to 11%)<xref ref-type="bibr" rid="article-17954.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Adverse Drug Reactions (1% to 10%)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Palpitations (3%), cold extremities (1% to 3%), prolonged QTc interval on ECG, increased diastolic blood pressure (5% to 9%), greater than or equal to 15 mmHg), systolic hypertension (4% to 5%), syncope (less than or equal to 3%), orthostatic hypotension (less than or equal to&#x000a0;2%), tachycardia (less than or equal to&#x000a0;2%)<xref ref-type="bibr" rid="article-17954.r15">[15]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fatigue (6% to 10%), dizziness (5% to 8%), depression (4% to 7%), disturbed sleep (3% to 7%), irritability (5% to 6%), jitteriness (2% to 5%), abnormal dreams (4%), chills (3%), paresthesia (adults 3%; postmarketing observation in children), anxiety (greater than or equal to 2%), hostility (children and adolescents 2%), emotional lability (1% to 2%), agitation, restlessness, seizures<xref ref-type="bibr" rid="article-17954.r16">[16]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Excoriation (2% to 4%), rash (2%), pruritus, urticaria,flushing (greater than or equal to&#x000a0;2%)weight loss (2% to 7%),&#x000a0; hot flash (3%), increased thirst (2%), menstrual disease, dyspepsia (4%), anorexia (3%), dysgeusia, flatulence, &#x000a0;urinary retention (1% to 6%), dysmenorrhea (3%), dysuria (2%),&#x000a0; pollakiuria, testicular pain, urinary frequency, tremor (1% to 5%), muscle spasm, weakness, blurred vision (1% to 4%), conjunctivitis (1% to 3%)decreased libido (3%), ejaculatory disorder (2% to 6%)<xref ref-type="bibr" rid="article-17954.r17">[17]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hepatotoxicity (hepatocellular with marked increases in serum aminotransferase level)&#x000a0;Likelihood score: C (probable cause of clinically apparent liver injury)<xref ref-type="bibr" rid="article-17954.r18">[18]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17954.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="bullet">
          <list-item>
            <p>Contraindications to atomoxetine include allergy to atomoxetine, use of an MAOI within the last 14 days, narrow-angle glaucoma, history of pheochromocytoma, and cardiac disorders, which can not tolerate increases in blood pressure or heart rate.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Drug Interactions: Because of the potential for interaction with CYP2D6 inhibitors (paroxetine, fluoxetine, and quinidine) dose of atomoxetine needs to be adjusted to prevent side effects from a higher concentration of atomoxetine.<xref ref-type="bibr" rid="article-17954.r19">[19]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Women of childbearing age should use appropriate contraceptive measures as the adverse effects of atomoxetine have not been investigated thoroughly during pregnancy. Women breastfeeding should exercise caution when taking atomoxetine as it is unknown if atomoxetine is excreted in breast milk.<xref ref-type="bibr" rid="article-17954.r20">[20]</xref></p>
          </list-item>
        </list>
        <p><bold>Boxed Warning&#x000a0;</bold>(Package Insert)</p>
        <list list-type="bullet">
          <list-item>
            <p>Suicidal ideation in adolescents &#x00026; children: Atomoxetine raised the risk of suicidal ideation in children or adolescents with (ADHD). Placebo-controlled trials of atomoxetine in adolescents &#x00026; children have shown a greater risk of suicidal ideation earlier during treatment in those receiving atomoxetine than in placebo. Therefore, patients who are started on therapy should be observed closely for suicidality. Clinicians should instruct caregivers on the need for close observation and communication with the clinician. The average risk of suicidal ideation in patients taking atomoxetine capsules was 0.4%.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17954.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <list list-type="bullet">
          <list-item>
            <p>Children prescribed atomoxetine should have their growth monitored. All patients started on atomoxetine should have their vital signs monitored. Also, all patients require monitoring for attention, hyperactivity, anxiety, aggression/hostility, and suicidal ideation.<xref ref-type="bibr" rid="article-17954.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>New mental (psychiatric) problems in children and teenagers:&#x000a0;new psychotic symptoms (such as hearing voices, believing things that are not true, being suspicious).</p>
          </list-item>
          <list-item>
            <p>Monitor for emergence of bipolar disorder/hypomania while the patient is on atomoxetine.<xref ref-type="bibr" rid="article-17954.r22">[22]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17954.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <list list-type="bullet">
          <list-item>
            <p>Exercise caution when prescribing atomoxetine with other medications metabolized via CYP2D6 as plasma concentrations can be significantly affected, leading to toxicity. Evidence regarding the toxicity of atomoxetine is limited, with much of the data coming from case studies of overdoses. Tachycardia, nausea, vomiting, and hypertension were among the most common symptoms of toxicity. Activated charcoal therapy and support of vital signs appear to be sufficient care during acute toxicity.<xref ref-type="bibr" rid="article-17954.r4">[4]</xref><xref ref-type="bibr" rid="article-17954.r23">[23]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The concomitant administration of atomoxetine and MAOIs, e.g., phenelzine, is contraindicated because the combination may increase the risk of serious and potentially fatal adverse events. It includes hyperthermia, rigidity, myoclonus, autonomic instability, extreme agitation, and mental status changes, leading to delirium and coma. A two-week washout period should occur between the discontinuation and initiation of either of these agents.<xref ref-type="bibr" rid="article-17954.r24">[24]</xref>&#x000a0;The clinician should consult with a Certified Poison Control Center. Atomoxetine is highly protein-bound; hence dialysis is not likely to be useful in treating overdose.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17954.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>When atomoxetine is used to treat ADHD, the health care team MDs, DOs, NPs, and PAs need to prescribe it carefully and monitor patients regularly, e.g., children's growth. Pharmacists should perform medication reconciliation and watch for potential drug interactions to report to the clinician. Nursing staff should record vital signs for patients at each clinic visit and provide consultation. Additionally, the medication can significantly affect behavior, and thus the healthcare team needs to monitor patients for anxiety, aggression/hostility, and suicidal ideation, especially in children. If adverse effects appear, discontinuing the drug might be necessary, and the clinician should refer the patient to a psychiatrist for a follow-up consultation. The outcomes for patients treated with atomoxetine can be fair; some patients respond positively, but adverse effects often reduce adherence. Thus communication between the healthcare team is vital for safety and optimal patient outcomes.[Level 5]</p>
      </sec>
      <sec id="article-17954.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17954&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17954">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17954/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17954">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17954.s11">
        <title>References</title>
        <ref id="article-17954.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nebhinani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Viswanathan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kirubakaran</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.</article-title>
            <source>Autism Res</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>542</fpage>
            <page-range>542-552</page-range>
            <pub-id pub-id-type="pmid">30653855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Byun</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Sunwoo</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension.</article-title>
            <source>Ann Clin Transl Neurol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>112</fpage>
            <page-range>112-120</page-range>
            <pub-id pub-id-type="pmid">31856425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Heo</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bahk</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Comparison between Atomoxetine and OROS Methylphenidate as an Adjunctive to SSRIs in Attention-deficit/Hyperactivity Disorder Adults with Comorbid Partially Responsive Major Depressive Disorder: A Head-to-head, 12-week, Randomized, Rater-blinded Clinical Trial.</article-title>
            <source>Clin Psychopharmacol Neurosci</source>
            <year>2022</year>
            <month>Feb</month>
            <day>28</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>143</fpage>
            <page-range>143-153</page-range>
            <pub-id pub-id-type="pmid">35078957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2016</year>
            <month>May</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>314</fpage>
            <page-range>314-26</page-range>
            <pub-id pub-id-type="pmid">26859445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>QQ</given-names>
              </name>
            </person-group>
            <article-title>The Mechanism, Clinical Efficacy, Safety, and Dosage Regimen of Atomoxetine for ADHD Therapy in Children: A Narrative Review.</article-title>
            <source>Front Psychiatry</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>780921</fpage>
            <pub-id pub-id-type="pmid">35222104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kielbasa</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kalvass</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Stratford</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>137</fpage>
            <page-range>137-42</page-range>
            <pub-id pub-id-type="pmid">18936112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sauer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ring</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Witcher</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of atomoxetine.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2005</year>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>571</fpage>
            <page-range>571-90</page-range>
            <pub-id pub-id-type="pmid">15910008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kobayashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Okunushi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ebata</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shiohama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sawada</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shimojo</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Facial nerve palsy associated with atomoxetine-induced hypertension.</article-title>
            <source>Brain Dev</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>310</fpage>
            <page-range>310-312</page-range>
            <pub-id pub-id-type="pmid">30314873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Update on Common Psychiatric Medications for Children.</article-title>
            <source>Pediatr Ann</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>47</volume>
            <issue>8</issue>
            <fpage>e311</fpage>
            <page-range>e311-e316</page-range>
            <pub-id pub-id-type="pmid">30102754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <chapter-title>Atomoxetine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garnock-Jones</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.</article-title>
            <source>Paediatr Drugs</source>
            <year>2009</year>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-26</page-range>
            <pub-id pub-id-type="pmid">19445548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pan</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Jonsson</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>&#x0015e;ahpazo&#x0011f;lu &#x000c7;akmak</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>H&#x000e4;ge</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hohmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nobel Norrman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Buitelaar</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Banaschewski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cortese</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coghill</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>B&#x000f6;lte</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis.</article-title>
            <source>Psychol Med</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-25</page-range>
            <pub-id pub-id-type="pmid">34635194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Grimsby</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Pediatric Priapism Secondary to Psychotherapeutic Medications.</article-title>
            <source>Urology</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>86</volume>
            <issue>2</issue>
            <fpage>376</fpage>
            <page-range>376-8</page-range>
            <pub-id pub-id-type="pmid">26199163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solmi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fornaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ostinelli</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Zangani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Croatto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Monaco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Krinitski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fusar-Poli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
            </person-group>
            <article-title>Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects.</article-title>
            <source>World Psychiatry</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>214</fpage>
            <page-range>214-232</page-range>
            <pub-id pub-id-type="pmid">32394557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hennissen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bakker</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Banaschewski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carucci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coghill</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Danckaerts</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dittmann</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Hollis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kovshoff</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nagy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sonuga-Barke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Zuddas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Buitelaar</surname>
                <given-names>JK</given-names>
              </name>
              <collab>ADDUCE consortium</collab>
            </person-group>
            <article-title>Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.</article-title>
            <source>CNS Drugs</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>199</fpage>
            <page-range>199-215</page-range>
            <pub-id pub-id-type="pmid">28236285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sawant</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Daviss</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Seizures and prolonged QTc with atomoxetine overdose.</article-title>
            <source>Am J Psychiatry</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>161</volume>
            <issue>4</issue>
            <fpage>757</fpage>
            <pub-id pub-id-type="pmid">15056530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goetz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Surman</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Prolonged penile erections associated with the use of atomoxetine and aripiprazole in an 11-year-old boy.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>275</fpage>
            <page-range>275-6</page-range>
            <pub-id pub-id-type="pmid">24577257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <chapter-title>Atomoxetine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">31643982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schoretsanitis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Leon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eap</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Paulzen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.</article-title>
            <source>CNS Drugs</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>12</issue>
            <fpage>1201</fpage>
            <page-range>1201-1222</page-range>
            <pub-id pub-id-type="pmid">31776871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alessi</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Spalding</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Atomoxetine and pregnancy.</article-title>
            <source>J Am Acad Child Adolesc Psychiatry</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>8</issue>
            <fpage>883</fpage>
            <page-range>883-4, author reply 884-5</page-range>
            <pub-id pub-id-type="pmid">12874488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanidir</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Tanidir</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ozturk</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bahali</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gunes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ergul</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Uneri</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Akdeniz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tuzcu</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Effects of atomoxetine on heart rhythm in children and adolescents.</article-title>
            <source>Pediatr Int</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>1078</fpage>
            <page-range>1078-85</page-range>
            <pub-id pub-id-type="pmid">26096186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Varambally</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Atomoxetine Induced Hypomania in a Patient with Bipolar Disorder and Adult Attention Deficit Hyperactivity Disorder.</article-title>
            <source>Indian J Psychol Med</source>
            <year>2017</year>
            <season>Jan-Feb</season>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>89</fpage>
            <page-range>89-91</page-range>
            <pub-id pub-id-type="pmid">28250566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spiller</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Hays</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Aleguas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.</article-title>
            <source>CNS Drugs</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>531</fpage>
            <page-range>531-43</page-range>
            <pub-id pub-id-type="pmid">23757186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17954.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brunt</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Contrucci</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Hondebrink</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Franssen</surname>
                <given-names>EJF</given-names>
              </name>
            </person-group>
            <article-title>Novel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review.</article-title>
            <source>Ther Drug Monit</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>271</fpage>
            <page-range>271-281</page-range>
            <pub-id pub-id-type="pmid">32022784</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
